Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients

S. Nishida; D. M. Levi; J. I. Moon; J. R. Madariaga; T. Kato; G. Selvaggi; P. Tryphonopoulos; W. DeFaria; S. Santiago; J. Gaynor; D. Weppler; E. Martinez; P. Ruiz; A. G. Tzakis

doi:10.1016/j.transproceed.2006.05.057

Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients

S. Nishida, D. M. Levi, J. I. Moon, J. R. Madariaga, T. Kato, G. Selvaggi, P. Tryphonopoulos, W. DeFaria, S. Santiago, J. Gaynor, D. Weppler, E. Martinez, P. Ruiz, A. G. Tzakis

Surgery

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.

Original language	English (US)
Pages (from-to)	1747-1749
Number of pages	3
Journal	Transplantation proceedings
Volume	38
Issue number	6
DOIs	https://doi.org/10.1016/j.transproceed.2006.05.057
State	Published - Jul 2006

ASJC Scopus subject areas

Surgery
Transplantation

Access to Document

10.1016/j.transproceed.2006.05.057

Fingerprint Dive into the research topics of 'Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients'. Together they form a unique fingerprint.

Cite this

Nishida, S., Levi, D. M., Moon, J. I., Madariaga, J. R., Kato, T., Selvaggi, G., Tryphonopoulos, P., DeFaria, W., Santiago, S., Gaynor, J., Weppler, D., Martinez, E., Ruiz, P., & Tzakis, A. G. (2006). Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients. Transplantation proceedings, 38(6), 1747-1749. https://doi.org/10.1016/j.transproceed.2006.05.057

Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients. / Nishida, S.; Levi, D. M.; Moon, J. I.; Madariaga, J. R.; Kato, T.; Selvaggi, G.; Tryphonopoulos, P.; DeFaria, W.; Santiago, S.; Gaynor, J.; Weppler, D.; Martinez, E.; Ruiz, P.; Tzakis, A. G.

In: Transplantation proceedings, Vol. 38, No. 6, 07.2006, p. 1747-1749.

Research output: Contribution to journal › Article › peer-review

Nishida, S, Levi, DM, Moon, JI, Madariaga, JR, Kato, T, Selvaggi, G, Tryphonopoulos, P, DeFaria, W, Santiago, S , Gaynor, J, Weppler, D, Martinez, E, Ruiz, P & Tzakis, AG 2006, 'Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients', Transplantation proceedings, vol. 38, no. 6, pp. 1747-1749. https://doi.org/10.1016/j.transproceed.2006.05.057

@article{94e400aa035842e1bd217e906467cf5e,

title = "Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients",

abstract = "Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.",

author = "S. Nishida and Levi, {D. M.} and Moon, {J. I.} and Madariaga, {J. R.} and T. Kato and G. Selvaggi and P. Tryphonopoulos and W. DeFaria and S. Santiago and J. Gaynor and D. Weppler and E. Martinez and P. Ruiz and Tzakis, {A. G.}",

year = "2006",

month = jul,

doi = "10.1016/j.transproceed.2006.05.057",

language = "English (US)",

volume = "38",

pages = "1747--1749",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "6",

}

TY - JOUR

T1 - Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients

AU - Nishida, S.

AU - Levi, D. M.

AU - Moon, J. I.

AU - Madariaga, J. R.

AU - Kato, T.

AU - Selvaggi, G.

AU - Tryphonopoulos, P.

AU - DeFaria, W.

AU - Santiago, S.

AU - Gaynor, J.

AU - Weppler, D.

AU - Martinez, E.

AU - Ruiz, P.

AU - Tzakis, A. G.

PY - 2006/7

Y1 - 2006/7

N2 - Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.

AB - Background: Alemtuzumab (Campath-1H [C1H]) is a humanized monoclonal antibody directed against the CD 52 antigen that is present on the surface of T cells, B cells, natural killer cells and monocytes. We studied its application in intestinal transplantation. Methods: This is a retrospective review of adult patients who underwent intestinal transplantation between December 1994 and May 2005. Group 1: non-C1H group (n = 39); group 2: C1H group (n = 37). C1H was administered as an induction immunosuppression in four doses (0.3 mg/kg), or in two doses (30 mg/kg). Tacrolimus levels were maintained at low level (5-10 ng/dL). No maintenance steroids were given. Results: One-year survival of group 1 and group 2 patients were 57% and 70%, respectively. This difference is not statistically significant. Of 37 patients in group 2, 21 are alive. The incidence of rejection was lower in group 2 (P < .005). Average current tacrolimus level is 6.97 ± 3.98 ng/dL. Seventeen patients (81%) are steroid free, and 15 (71%) are maintained solely on tacrolimus. There was no graft versus host disease in group 2. Conclusions: Our preliminary data suggest that C1H can provide effective immunosuppression for intestinal transplantation. Incidence of rejection was less with this regimen using low maintenance tacrolimus and minimal steroids.

UR - http://www.scopus.com/inward/record.url?scp=33746867891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746867891&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2006.05.057

DO - 10.1016/j.transproceed.2006.05.057

M3 - Article

C2 - 16908270

AN - SCOPUS:33746867891

VL - 38

SP - 1747

EP - 1749

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 6

ER -

Intestinal Transplantation With Alemtuzumab (Campath-1H) Induction for Adult Patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this